search
Back to results

Exacerbation Self-management in COPD: The ACCESS Study (ACCESS)

Primary Purpose

Chronic Obstructive Pulmonary Disease (COPD)

Status
Unknown status
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
ACCESS
Sponsored by
Radboud University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Chronic Obstructive Pulmonary Disease (COPD) focused on measuring exacerbations, self-management support, software application

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • confirmed diagnosis of COPD by spirometry (post-bronchodilator FEV1/FVC < 0.70);
  • at least 2 self-reported exacerbations in the previous 12 months, i.e. a change for ≥ 2 consecutive days in either ≥ 2 major symptoms (dyspnea, sputum purulence, sputum amount) or any 1 major symptom plus any ≥ 1 minor symptoms (colds, wheeze, sore throat, cough).

Exclusion Criteria:

  • severe co-morbid conditions that prohibit participation;
  • unable to communicate in the Dutch language;
  • difficulties using a smartphone;

Sites / Locations

  • Radboud University Medical Centre, Department of Primary and Community Care

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

ACCESS

paper plan

Arm Description

ACCESS is used when participants experience more COPD symptoms.

Paper exacerbation action plan is used when participants experience more COPD symptoms.

Outcomes

Primary Outcome Measures

Number of exacerbation-free weeks
Measured with the Telephonic EXacerbation Assessment System (TEXAS) [Bischoff, ERJ, 2012]

Secondary Outcome Measures

Improvement in exacerbation-related self-management behaviour
Prompt reaction and adequate response to symptoms, measured with the Telephonic EXacerbation Assessment System (TEXAS) [Bischoff, ERJ, 2012]
Improvement in Quality of Life
Measured with the Nijmegen Clinical Screening Instrument (NCSI)
Improvement in Quality of Life
Measured with the Clinical COPD Questionnaire (CCQ)
Improvement in Quality of Life
Measured with the Euroqol -5 dimensions (EQ-5d)
Improvement in self-efficacy
Measured with an exacerbation-related self-efficacy scale
Number of ER visits and hospital admissions
Measured with hospital and general practice medical records
Cost-effectiveness of ACCESS; ratio calculated with the use of medical records and questionnaires.
Costs consist of health care utilisation and patients' productivity losses, effectiveness is measured with EQ-5d.

Full Information

First Posted
August 5, 2015
Last Updated
August 29, 2017
Sponsor
Radboud University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT02553096
Brief Title
Exacerbation Self-management in COPD: The ACCESS Study
Acronym
ACCESS
Official Title
Adaptive Computerized COPD Exacerbation Self-management Support (ACCESS): A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Unknown status
Study Start Date
June 2015 (Actual)
Primary Completion Date
August 2017 (Actual)
Study Completion Date
September 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Radboud University Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Aim is to test the effect of ACCESS ("Adaptive Computerized COPD Exacerbation Self-management Support"), a software application designed to support patients with COPD in self-management of exacerbations.
Detailed Description
Rationale: COPD exacerbations considerably affect patients' health status and contribute to COPD related costs. Patients often have problems in recognizing and responding promptly to exacerbations. Tools that support patients in exacerbation self-management such as paper exacerbation action plans and telemonitoring systems have shown some positive results on exacerbation related outcomes. However, many patients appear not to adhere to their action plan instructions. Besides, existing telemonitoring tools rely heavily on the input of healthcare professionals which makes it difficult to assess the true effects and cost effectiveness of telemonitoring systems. Recently, the Radboud University has developed the "Adaptive Computerized COPD Exacerbation Self-management Support" (ACCESS) system. This software application integrates objective parameters, such as spirometry, pulse-oximetry, temperature, and self-reported symptom worsening into a Bayesian network model resulting in a weighted exacerbation risk prediction. Patients are able to monitor themselves at any given moment. The ACCESS system not only predicts whether an exacerbation is imminent, but also provides ad hoc tailored advice without interference of a healthcare professional. Objective: In this project the primary aim is to assess the (cost-)effectiveness of the ACCESS system in the support of exacerbation self-management in patients with COPD. Study design: A multicenter, pragmatic, two-arm, randomized controlled trial with a follow-up of 12 months per participant. Study population: Patients with COPD, > 40 years old, with 2 or more self-reported symptom based exacerbations in the previous year. Intervention: After a short self-management educational session on exacerbations, participants are randomized to either 1) exacerbation self-management support through the use of a paper exacerbation action plan (control group); or 2) exacerbation self-management support through the use of the ACCESS system (intervention group). Participants in the intervention group are instructed to use ACCESS when they notice a change in COPD symptoms. Participants in the control group are instructed to use their paper action plan when they notice a change in COPD symptoms. Main study parameters/endpoints: Primary aim: to increase the number of exacerbation-free weeks. Secondary aims: to improve exacerbation self-management, exacerbation-management related self-efficacy, and quality of life. To decrease ER visits, hospital admissions and COPD related costs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease (COPD)
Keywords
exacerbations, self-management support, software application

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
2-block randomised trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
87 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ACCESS
Arm Type
Experimental
Arm Description
ACCESS is used when participants experience more COPD symptoms.
Arm Title
paper plan
Arm Type
No Intervention
Arm Description
Paper exacerbation action plan is used when participants experience more COPD symptoms.
Intervention Type
Device
Intervention Name(s)
ACCESS
Intervention Description
The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
Primary Outcome Measure Information:
Title
Number of exacerbation-free weeks
Description
Measured with the Telephonic EXacerbation Assessment System (TEXAS) [Bischoff, ERJ, 2012]
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Improvement in exacerbation-related self-management behaviour
Description
Prompt reaction and adequate response to symptoms, measured with the Telephonic EXacerbation Assessment System (TEXAS) [Bischoff, ERJ, 2012]
Time Frame
1 year
Title
Improvement in Quality of Life
Description
Measured with the Nijmegen Clinical Screening Instrument (NCSI)
Time Frame
1 year
Title
Improvement in Quality of Life
Description
Measured with the Clinical COPD Questionnaire (CCQ)
Time Frame
1 year
Title
Improvement in Quality of Life
Description
Measured with the Euroqol -5 dimensions (EQ-5d)
Time Frame
1 year
Title
Improvement in self-efficacy
Description
Measured with an exacerbation-related self-efficacy scale
Time Frame
1 year
Title
Number of ER visits and hospital admissions
Description
Measured with hospital and general practice medical records
Time Frame
1 year
Title
Cost-effectiveness of ACCESS; ratio calculated with the use of medical records and questionnaires.
Description
Costs consist of health care utilisation and patients' productivity losses, effectiveness is measured with EQ-5d.
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: confirmed diagnosis of COPD by spirometry (post-bronchodilator FEV1/FVC < 0.70); at least 2 self-reported exacerbations in the previous 12 months, i.e. a change for ≥ 2 consecutive days in either ≥ 2 major symptoms (dyspnea, sputum purulence, sputum amount) or any 1 major symptom plus any ≥ 1 minor symptoms (colds, wheeze, sore throat, cough). Exclusion Criteria: severe co-morbid conditions that prohibit participation; unable to communicate in the Dutch language; difficulties using a smartphone;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tjard Schermer, PhD
Organizational Affiliation
head of research unit
Official's Role
Principal Investigator
Facility Information:
Facility Name
Radboud University Medical Centre, Department of Primary and Community Care
City
Nijmegen
ZIP/Postal Code
6500 HB
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
23500485
Citation
van der Heijden M, Lucas PJ, Lijnse B, Heijdra YF, Schermer TR. An autonomous mobile system for the management of COPD. J Biomed Inform. 2013 Jun;46(3):458-69. doi: 10.1016/j.jbi.2013.03.003. Epub 2013 Mar 15.
Results Reference
background
PubMed Identifier
21920893
Citation
Bischoff EW, Boer LM, Molema J, Akkermans R, van Weel C, Vercoulen JH, Schermer TR. Validity of an automated telephonic system to assess COPD exacerbation rates. Eur Respir J. 2012 May;39(5):1090-6. doi: 10.1183/09031936.00057811. Epub 2011 Sep 15.
Results Reference
background
PubMed Identifier
21037270
Citation
Bischoff EW, Hamd DH, Sedeno M, Benedetti A, Schermer TR, Bernard S, Maltais F, Bourbeau J. Effects of written action plan adherence on COPD exacerbation recovery. Thorax. 2011 Jan;66(1):26-31. doi: 10.1136/thx.2009.127621. Epub 2010 Oct 30.
Results Reference
background
PubMed Identifier
24361389
Citation
van der Heijden M, Velikova M, Lucas PJ. Learning Bayesian networks for clinical time series analysis. J Biomed Inform. 2014 Apr;48:94-105. doi: 10.1016/j.jbi.2013.12.007. Epub 2013 Dec 18.
Results Reference
background
PubMed Identifier
24183893
Citation
van der Heijden M, Lucas PJ. Describing disease processes using a probabilistic logic of qualitative time. Artif Intell Med. 2013 Nov;59(3):143-55. doi: 10.1016/j.artmed.2013.09.003. Epub 2013 Oct 7.
Results Reference
background
PubMed Identifier
31599729
Citation
Boer L, Bischoff E, van der Heijden M, Lucas P, Akkermans R, Vercoulen J, Heijdra Y, Assendelft W, Schermer T. A Smart Mobile Health Tool Versus a Paper Action Plan to Support Self-Management of Chronic Obstructive Pulmonary Disease Exacerbations: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2019 Oct 9;7(10):e14408. doi: 10.2196/14408.
Results Reference
derived
PubMed Identifier
30683464
Citation
Liu M, Stella F, Hommersom A, Lucas PJF, Boer L, Bischoff E. A comparison between discrete and continuous time Bayesian networks in learning from clinical time series data with irregularity. Artif Intell Med. 2019 Apr;95:104-117. doi: 10.1016/j.artmed.2018.10.002. Epub 2019 Jan 22.
Results Reference
derived

Learn more about this trial

Exacerbation Self-management in COPD: The ACCESS Study

We'll reach out to this number within 24 hrs